To support Healthy China, "AI+ weight loss" is implemented, FANGZHOU JIANKE (06086) releases ecological value and opens up growth space.
Ark Genius's practice achievements showcased at the conference also provide the industry with paths and models that can be used for reference. From the perspective of the capital market, the company's proven profit model and growth potential will continue to be recognized. With the release of value from "AI+ weight loss," it is expected to become a core target in the "AI+ medical health" field.
At the present moment, a quiet revolution on "AI + weight loss" is taking place. Currently, the issue of overweight and obesity among Chinese residents is severe and has become a core issue in public health governance. The country has upgraded weight management to a strategic direction through various policies, while AI technology provides a breakthrough solution for scientific weight loss.
On October 22, the "Health China AI + Weight Management Pioneer" industry collaborative innovation seminar was held at the National People's Congress Center. This weight loss conference was organized by the CHINA FOODS Drug Quality and Safety Promotion Association, aiming to promote collaboration between "regulation-academic-enterprise" and establish industry consensus and innovative mechanisms for AI-empowered weight management.
At the same time, the practical results presented by FANGZHOU JIANKE at the conference also provided a path and model for the industry to learn from. From a capital market perspective, the company's verified profit model and growth potential continue to be recognized, and with the release of the value of "AI + weight loss", it is expected to become a core target in the "AI + medical health" field.
Driven by policies and demand, "AI + weight loss" welcomes the eve of an outbreak
In recent years, the issue of overweight and obesity in China has triggered a profound transformation in the weight management industry. Abnormal weight is an important risk factor for cardiovascular and cerebrovascular diseases, diabetes, and some cancers, threatening national health and increasing the burden on medical resources. In this context, the country has continuously issued policies to promote weight management: launching the "Weight Management Year" campaign in 2024 to establish a supportive environment; in April 2025, the National Health and Family Planning Commission further included healthy weight management action in the Healthy China Action, marking the formal entry of weight management into the "national public health governance" category.
From the perspective of market demand, consumers' demand for "scientific, effective, and sustainable" weight loss solutions has entered an outbreak period. As obesity is often accompanied by a variety of complications, users have an urgent need for scientific weight loss solutions, a strong willingness to pay, and a vast market space. The weight loss process heavily relies on continuous, personalized intervention and guidance, which aligns well with AI's capabilities in data analysis, program generation, and real-time feedback.
Therefore, "AI + weight loss" is seen as the shortest path, with the most intuitive user experience, and the most certain commercial return among the comprehensive applications of chronic disease management. From a global perspective, overseas companies such as Noom and Hims & Hers Health have explored mature models in the field of "AI + weight loss". Domestic leading companies can not only learn from international experience but also optimize according to the characteristics of the Chinese market, thus having stronger localization advantages.
At present, China not only has stronger policy support, providing policy dividends for the popularization of "AI + weight loss", but also has a larger user base, providing a soil for scalable implementation. As a pioneer in AI+ chronic disease management, FANGZHOU JIANKE's verified business model and technological capabilities, tailored to the Chinese medical system, help doctors efficiently serve users, connect pharmaceutical companies to achieve a "diagnosis-treatment-drug" closed-loop, making its layout in weight management seem to be a foregone conclusion.
Leading by technology, the construction of the "AI + H2H" system provides a competitive advantage that is hard to replicate
In the "AI + weight loss" track, FANGZHOU JIANKE's core competitiveness lies in its creation of an "AI technology + ecological network + service capabilities" integrated system with the "AI + H2H" ecosystem. This system not only connects the entire chain of "users-doctors-pharmaceutical companies" but also improves the operational efficiency of the entire ecosystem through technological empowerment.
It is understood that in response to the current pain points of weight loss, such as "fragmented solutions, difficult to sustain results, lack of safety guarantees", FANGZHOU JIANKE relies on its resources and data advantages in the chronic disease management field to create the industry's first "AI + weight loss" data intelligent solution: using their self-developed Xingshi Medical Big Model as a technological foundation, AI doctor assistants, AI health managers, and AI medication assistants are linked to both ends of the doctor-patient relationship to apply AI technology to the entire weight loss service process.
Specifically, when a user wants weight loss advice, they only need to send their medical report, BMI data, and instructions to the AI health manager, who can then use algorithms to integrate data such as age, weight, underlying diseases, and metabolic indicators to generate personalized weight loss recommendations.
On the other hand, for obese patients with medication needs, the platform's AI medication assistant can provide professional answers 24/7. In cases requiring in-depth medication consultation, the platform can match them with professional consultants with medical backgrounds to ensure a safe and scientific process.
In addition, unlike most companies in the industry exploring "AI weight loss from scratch", FANGZHOU JIANKE's advantage lies in reusing its mature chronic disease management capabilities in the weight management scenario. Previously, it had verified the effectiveness of the "AI + doctor-patient interaction + medication management" model in areas such as hypertension and diabetes, and as weight loss is an extension of chronic disease management, it can directly use the core capabilities of this model, including medical-patient communication systems, medication management capabilities, and user operation experience.
This also gives FANGZHOU JIANKE a significant advantage at the implementation level: weight loss and chronic disease management have a natural "scene overlap", as obesity is a cause of many chronic diseases, weight loss solutions deeply integrate with the diagnosis and treatment processes of chronic diseases. FANGZHOU JIANKE's mature experience in "AI + chronic disease management" can enable them to quickly achieve scalable and rapid implementation of "AI + weight loss" within the industry.
At the same time, FANGZHOU JIANKE's layout of "AI + weight loss" will further drive its profit certainty. Its platform's paying users show clear health management needs and user stickiness: with a high repurchase rate of 85.4% and a prescription drug ratio of 81.7%, indicating that many users require long-term, professional support. With its "personal doctor-patient" model, the platform has successfully targeted users with high willingness to pay and high stickiness.
Furthermore, several key data points in FANGZHOU JIANKE's mid-term performance further highlight the health of its ecosystem and business potential: the high repurchase rate reflects user recognition of the platform's services, the high proportion of prescription drugs demonstrates the model's advantages of combining weight loss and chronic disease management, and the 34.4% year-on-year increase in monthly active users shows that the platform is still in a period of rapid growth.
Based on this high-quality data, by mid-2025 FANGZHOU JIANKE successfully achieved turning loss into profit, with a net profit of 12.5 million yuan, and an adjusted year-on-year net profit growth of 16.8% to 17.6 million yuan. This milestone performance not only marks the commercial model's entry into a profit realization period after years of refinement but also verifies the effectiveness of the "AI + H2H" ecosystem in commercial value conversion.
Overall, AI technology is not only the "technical support" for FANGZHOU JIANKE's ecosystem but also its "value magnifier": on one hand, AI replaces most manual services (such as basic consulting, data organization), reducing service costs and expanding profit space; on the other hand, AI enhances user stickiness through "real-time interaction + data visualization", promotes the conversion from "single service" to "long-term health management consumption", digs into demand based on user data, extends value-added services such as physical examination and health insurance, and builds a consumption chain of "weight loss-chronic disease management-full-cycle health services".
Conclusion
At the point of 2025, "AI + weight loss" has entered a critical stage of "scalable implementation", with FANGZHOU JIANKE leading the way with its verified business model, mature ecosystem, and technological advantages. From an industry perspective, FANGZHOU JIANKE's practices provide replicable standards for "AI + weight loss", advancing the industry from "fragmented services" to "systematic solutions". Its services will not only promote the popularization of health weight management among the population but also reduce service costs through AI, allowing users to access scientific weight loss solutions throughout their lifecycle and striving to achieve the goals of the "Weight Management Year".
In fact, transitioning from "passive intervention" to "active management", weight management is a long-term, systematic endeavor that requires the strengths of all parties and deep cooperation. Dr. Xie Fangmin, founder, chairman, and CEO of FANGZHOU JIANKE, stated that the company will always start from the core health needs of the nation, continually expand the depth and breadth of the application scenarios of "AI + weight loss", and look forward to collaborating with partners in the medical, scientific research, and industrial fields to build a more comprehensive weight management service system, allowing scientific weight loss to benefit a wider population and strengthen the nation's health defense.
In summary, driven by the triple forces of policy, demand, and technology, the golden period of the "AI + weight loss" track has arrived. With its core barrier built on the "AI + H2H" ecosystem, FANGZHOU JIANKE is transitioning from an "industry participant" to an "industry leader" and is expected to continue delivering value under the strategy of Healthy China, driving the broader implementation of "AI + weight loss" and contributing to the transformation of national health and medical industries.
Related Articles

US Stock Market Move | AnPheNo (APH.US) rose more than 4% with a 106.29% year-on-year increase in net profit for the third quarter of the 2025 fiscal year.
US Stock Market Move | American Airlines Group Inc. (AAL.US) raised its profit forecast for 2025 by more than 5%.

US Stock Market Move | STMicroelectronics NV ADR RegS (STM.US) fell over 12% with Q3 operating profit below expectations.
US Stock Market Move | AnPheNo (APH.US) rose more than 4% with a 106.29% year-on-year increase in net profit for the third quarter of the 2025 fiscal year.

US Stock Market Move | American Airlines Group Inc. (AAL.US) raised its profit forecast for 2025 by more than 5%.
US Stock Market Move | STMicroelectronics NV ADR RegS (STM.US) fell over 12% with Q3 operating profit below expectations.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025